SCHEMBL3980449

SCHEMBL3980449

CCN(CC)CCCNc1nc(-c2ccc(-c3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc12

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.78
POLB P06746 2/20 0.64
FLT3 P36888 9/20 0.58
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
PDGFRB P09619 1/20 0.55
KIT P10721 1/20 0.55
PIK3CA P42336 1/20 0.55
HMOX1 P09601 1/20 0.51
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.49
CDK1 P06493 1/20 0.48
RAD52 P43351 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
KDM1A O60341 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670648 0.95 SLC2A1 (0.80) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3972870 0.93 SLC2A1 (0.70) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3974647 0.92 FLT3 (0.70) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3973291 0.88 SLC2A1 (0.64) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL6671471 0.88 SLC2A1 (0.70) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3972522 0.87 SLC2A1 (0.63) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3976619 0.86 SLC2A1 (0.64) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3973379 0.86 SLC2A1 (0.64) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3974901 0.85 SLC2A1 (0.72) SLC2A1POLBFLT3MEN1KMT2A
SCHEMBL3979948 0.85 SLC2A1 (0.60) SLC2A1POLBFLT3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 SLC2A1 1107/4885POLB 4723/4885FLT3 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.